© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
KalVista wins grant for DME treatment
Nov 19, 2012
KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.